A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patien… (NCT03512197) | Clinical Trial Compass
CompletedPhase 3
A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)
United States, Argentina, Australia511 participantsStarted 2018-07-20
Plain-language summary
The purpose of this study was to confirm the preliminary evidence from early clinical trials that midostaurin may provide clinical benefit not only to AML patients with the FLT3-mutations but also in FLT3-MN (SR\<0.05) AML (FLT3 mutant to wild type signal ratio below the 0.05 clinical cut-off).
This study evaluated the efficacy and safety of midostaurin in combination with daunorubicin or idarubicin and cytarabine for induction and intermediate-dose cytarabine for consolidation, and midostaurin single agent post-consolidation therapy in newly diagnosed patients with FLT3-MN (SR\<0.05) AML.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Diagnosis of AML (≥20% blasts in the bone marrow based on WHO 2016 classification). Patients with APL with PML-RARA are not eligible.
✓. Suitability for intensive induction chemotherapy in the judgment of the investigator
✓. Documented absence of an ITD and TKD activating mutation at codons D835 and I836 in the FLT3 gene, as determined by analysis in a Novartis designated laboratory using a validated clinical trial assay with clinical cutoff of 0.05 mutant to wild type signal ratio
✓. Age ≥18 years
✓. Laboratory values that indicate adequate organ function assessed locally at the screening visit
Exclusion criteria
✕. Central nervous system (CNS) leukemia
✕. Therapy-related secondary AML
✕. Isolated extramedullary leukemia
✕. Prior therapy for leukemia or myelodysplasia
What they're measuring
1
Event Free Survival (EFS)
Timeframe: From date of Randomization up to approx. 30 months